Do you hear that? That’s the sound of some mighty back-slapping at Uroplasty Inc.’s (NASDAQ:UPI) headquarters in Minnetonka, Minnesota.
After winning Medicare reimbursement Wednesday for its urinary incontinence therapy, the company has seen its stock price jump more than 20 percent to around $5.35 per share.
Uroplasty estimates Medicare will pay a base price of $97.49 per procedure, during which a pulse generator shoots low levels of electricity into the spinal nerves that control bladder function.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
However, Charles Haff, an analyst with Dougherty & Co., an investment bank in Minneapolis, thinks doctors will ultimately receive $126.47 per procedure.
Haff breaks it down this way: $65 to Uroplasty and $61.50 to the physician. Assuming the patient receives 12 neurostimulation sessions, doctors would generate revenue of $738 per patient. That’s well above the $450 doctors told Haff they would need in order to adopt the technology.
“With this higher-than-expected profitability for physicians to prescribe Urgent PC for their patients, we expect much more rapid adoption of the technology,” Haff wrote in a research note. “We would be strong buyers of the stock here.”
As a result, Haff boosted his fiscal 2012 sales forecast for Uroplasty to $26.1 million from $18.2 million. He also upgraded his fiscal 2013 sales estimate to nearly $40 million from $28.7 million.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
